Lates News

According to AI flash news, Tianfeng Securities released a research report on May 3, giving a buy rating to CStone Pharmaceuticals (688136.SH). The rating reasons mainly include: 1) the innovative platform is gradually entering the harvest period, with a high degree of target innovation, and has the potential to go global; 2) the progress of overseas business is smooth, and has partnered with multiple pharmaceutical companies, making the product selection more diverse. (Daily Economic News)